Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Xiubao Ren, M.D, Ph.D
CONTACT
Liang Liu, M.D, Ph.D
CONTACT
Lead
Tianjin Medical University Cancer Institute and Hospital
In the stage IIIB/IIIC/IV NSCLC, patients received Toripalimab Injection (PD-1 inhibitor) 240mg, d1; CTL cells venous re-transfusion \>=1x10\^9, d14; Q3W; till disease progresion, or intolerable adverse reactions.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
